A promising approach to targeting type 1 IFN in systemic lupus erythematosus
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A promising approach to targeting type 1 IFN in systemic lupus erythematosus
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 129, Issue 3, Pages 958-961
Publisher
American Society for Clinical Investigation
Online
2019-02-18
DOI
10.1172/jci127101
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
- (2019) Richard Furie et al. JOURNAL OF CLINICAL INVESTIGATION
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- SLE mortality remains disproportionately high, despite improvements over the last decade
- (2018) R R Singh et al. LUPUS
- Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus
- (2018) Joan T. Merrill et al. Arthritis & Rheumatology
- Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
- (2018) Ronald F van Vollenhoven et al. LANCET
- Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned
- (2017) L J Forbess et al. LUPUS
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
- (2017) Richard Furie et al. Arthritis & Rheumatology
- Remission in systemic lupus erythematosus: durable remission is rare
- (2016) Theresa R Wilhelm et al. ANNALS OF THE RHEUMATIC DISEASES
- Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
- (2016) Munther Khamashta et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
- (2016) Daniel J Wallace et al. ANNALS OF THE RHEUMATIC DISEASES
- Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience
- (2016) D J Wallace LUPUS
- New insights into the immunopathogenesis of systemic lupus erythematosus
- (2016) George C. Tsokos et al. Nature Reviews Rheumatology
- A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
- (2015) Kenneth C Kalunian et al. ANNALS OF THE RHEUMATIC DISEASES
- IFNα Inducible Models of Murine SLE
- (2013) Zheng Liu et al. Frontiers in Immunology
- Belimumab Is Approved by the FDA: What More Do We Need to Know to Optimize Decision Making?
- (2012) Diane Lewis Horowitz et al. Current Rheumatology Reports
- Health-Related Quality of Life and Employment Among Persons with Systemic Lupus Erythematosus
- (2010) Jinoos Yazdany et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients
- (2008) Pingping Wu et al. CLINICAL IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now